Acute Bacterial Skin and Skin Structure Infections Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.86 billion in 2024 to $10.5 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to public health initiatives, adoption of telemedicine and remote monitoring, improved emergency medical services, demand for patient education.

The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $13.3 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to demand for personalized medicine, increase in interventional cardiology, increasing awareness, global aging population. Major trends in the forecast period include advancements in diagnostic tools, integration of health information technology, rapid response systems, technological advancements.

The growth of the acute coronary syndrome market is expected to be fueled by the increasing prevalence of chronic diseases like coronary artery disease, ischemic heart disease, and vascular diseases. Ischemic heart disease, characterized by the narrowing or obstruction of coronary arteries, is one such chronic condition. The treatment of acute coronary syndrome (ACS) focuses on promptly alleviating symptoms, minimizing heart damage, and preventing further complications, especially for patients dealing with conditions like ischemic heart disease and vascular diseases. For instance, in August 2022 a study published in the Journal of the American College of Cardiology highlighted an anticipated rise in all four cardiovascular risk factors among the general U.S. population from 2025 to 2060. Dyslipidemia was projected to increase by 27.6%, while hypertension by 25.1%. The study also noted significant anticipated increases in rates of heart failure (33.4%) and ischemic heart disease (30.7%), followed by heart attacks (16.9%) and strokes (33.8%). This underscores how the prevalence of chronic diseases, including coronary artery disease, ischemic heart disease, and vascular diseases, is a driving force behind the acute coronary syndrome market's growth.

The growth of the acute coronary syndrome market is expected to be driven by rising healthcare expenditures. Healthcare expenditures refer to the total amount spent on healthcare services, products, and activities over a specific period, which can be measured at individual, community, national, or global levels. These expenditures are increasing due to factors such as the growing prevalence of chronic diseases, an aging population, advancements in medical technology, and a higher demand for more advanced healthcare services and treatments. As healthcare spending increases, it supports the development of improved diagnostic technologies, advanced therapies, and comprehensive treatment options, which are essential for addressing the growing need for cardiovascular care. For example, in May 2023, the Office for National Statistics reported that healthcare spending in the UK was approximately $362.08 billion (£292 billion), marking a 5.6% increase from the previous year. Additionally, long-term health and social care spending saw a real-term increase of 2.8% in 2022. As a result, rising healthcare expenditures will continue to fuel the growth of the acute coronary syndrome market.

The key players in the acute coronary syndrome market are focusing on the development of groundbreaking drugs to advance the treatment of acute coronary syndrome and maintain their market standing. These innovations in drug development have the potential to enhance the effectiveness of ACS treatment, streamlining the process for each patient in terms of time and resources. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, introduced Lodoco, the first anti-inflammatory atheroprotective cardiovascular treatment approved by the Food and Drug Administration (FDA). This medication is designed to reduce the risk of heart stroke, coronary revascularization, myocardial infarction (MI), and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.

In May 2023, Avertix Medical Inc., a US-based company specializing in the development of implantable patient alerting systems for acute coronary syndrome (ACS), entered a merger agreement with BIOS Acquisition Corporation for an approximate sum of $195 million. This strategic merger positions Avertix to enhance its commercial portfolio and further advance its innovative products, providing both patients and healthcare providers with state-of-the-art tools. BIOS Acquisition Corporation is a US-based incorporated blank check company.

Major companies operating in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

North America was the largest region in the acute coronary syndrome market in 2024. The regions covered in acute coronary syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acute coronary syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute coronary syndrome market consists of revenues earned by entities by providing various diagnoses through cardiac enzyme tests, blood tests and echocardiograms. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute coronary syndrome market also consists of sales of percutaneous coronary intervention (PCI) drugs and angiotensin-converting enzyme (ACE) inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions resulting from a sudden reduction in blood flow to the heart. ACS is characterized by symptoms like chest pain or discomfort (angina), along with indicators of cardiac distress such as shortness of breath and dizziness. The primary objective in treating ACS is to swiftly alleviate symptoms, mitigate heart damage, and prevent potential complications.

There are three main types of acute coronary syndrome such as non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), and unstable angina. NSTEMI denotes a type of heart attack where one or more coronary arteries are partially or completely obstructed, leading to reduced blood supply to the heart muscle. Treatment modalities encompass medications like statins, beta-blockers, ACE inhibitors, anticoagulants, among others. Diagnostic procedures include stress tests, blood tests, various imaging techniques, and more. These treatments can be administered orally or through parenteral routes, and they are employed across a range of end-users including hospitals, specialty clinics, and others.

The acute coronary syndrome market research report is one of a series of new reports that provides acute coronary syndrome market statistics, including acute coronary syndrome industry global market size, regional shares, competitors with an acute coronary syndrome market share, detailed acute coronary syndrome market segments, market trends and opportunities and any further data you may need to thrive in the acute coronary syndrome industry. This acute coronary syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.